Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB242 vs Infliximab in Rheumatoid Arthritis (Phase III)
CTR20170127Phase 3Completed
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Jul 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab-axxq in rheumatoid arthritis (RA), sponsored by Jacobio Pharmaceuticals. Started Jul 2017; status: completed.
02
Drugs
infliximab-axxq
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20170127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170127.